MedPath

Lipella Pharmaceuticals

Lipella Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2005-01-01
Employees
7
Market Cap
$3.7M
Website
http://www.lipella.com
globenewswire.com
·

Comprehensive Insight into Lichen Planus Pipeline Landscape Revealed for 2024

The 'Lichen Planus- Pipeline Insight, 2024' report evaluates emerging therapies and key players in the LP pipeline, highlighting the unmet need for specific pharmacotherapy. Notable developments include Lipella Pharmaceuticals â—‹ ' LP-310 â—‹ in Phase II trials for oral Lichen Planus. Key players like Incyte â—‹ and AFYX Therapeutics â—‹ contribute to innovative approaches, signaling promising future treatment options.
globenewswire.com
·

Comprehensive Insight into Lichen Planus Pipeline Landscape

The 'Lichen Planus- Pipeline Insight, 2024' report evaluates emerging therapies and key players in the Lichen Planus pipeline, highlighting the unmet need for specific pharmacotherapy. Notable developments include Lipella Pharmaceuticals â—‹ ' LP-310 in Phase II trials for oral Lichen Planus, alongside advancements by Incyte â—‹ and AFYX Therapeutics â—‹ . The report underscores industry and academic efforts towards innovative LP treatments, offering hope for improved patient care.
pharmabiz.com
·

Lipella Pharma completes dosing for first cohort in phase 2a trial of LP-310 for oral lichen planus

Lipella Pharmaceuticals â—‹ completed dosing for the first cohort in its phase 2a trial of LP-310 â—‹ , a liposomal- tacrolimus â—‹ oral rinse for oral lichen planus (OLP). No serious adverse events were reported, and pharmacokinetic data showed minimal systemic exposure. The trial will advance to evaluate a higher dose of 0.5 mg. Top-line data is expected by year-end 2024, with the trial concluding by mid-2025.
biospace.com
·

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310

Lipella Pharmaceuticals completes first cohort dosing in Phase 2a trial of LP-310 â—‹ , a liposomal- tacrolimus â—‹ oral rinse for Oral Lichen Planus, with no serious adverse events reported. The trial advances to higher doses, aiming for top-line data by year-end 2024 and trial completion by mid-2025.
globenewswire.com
·

Lipella Pharmaceuticals Secures Extended Market Exclusivity

Lipella Pharmaceuticals Inc. ○ announced the issuance of U.S. Patent No. 12,138,345 for its liposomal drug delivery platform, covering the use of metastable liposomes to deliver therapeutic agents. This patent extends market exclusivity for Lipella’s lead assets, LP-10 and LP-310, currently in Phase 2 trials for hemorrhagic cystitis and oral lichen planus, respectively.
citybiz.co
·

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals Inc. â—‹ plans a 1-for-8 reverse stock split effective Nov. 7, 2024, aiming to meet Nasdaq's minimum bid price requirement. The split will convert eight shares into one, with trading on a split-adjusted basis starting Nov. 8, 2024, under the symbol 'LIPO'. The CUSIP number will update to 53630L209. The split does not affect authorized shares or par value.
globenewswire.com
·

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals â—‹ , Inc. announces CEO Jonathan Kaufman, PhD will present at the 2024 Spartan Capital â—‹ Investor Conference on Nov 4, 2024, at 9:25 am EST in New York. Kaufman will also meet with registered investors. Lipella focuses on developing new drugs from existing generic drugs for diseases with significant unmet needs.
biospace.com
·

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug

Lipella Pharmaceuticals receives USPTO notice of allowance for its liposomal drug delivery platform, enhancing IP protection and market exclusivity for Phase 2 assets LP-10 and LP-310, targeting oncology, cancer survivorship, and immunotherapy.
globenewswire.com
·

Lipella Pharmaceuticals Announces U.S. Patent Allowance for

Lipella Pharmaceuticals receives USPTO notice of allowance for its liposomal drug delivery platform, enhancing IP protection and market exclusivity for its Phase 2 assets, LP-10 and LP-310, targeting hemorrhagic cystitis and oral lichen planus.
© Copyright 2025. All Rights Reserved by MedPath